Travere Therapeutics, Inc.
TVTX
$28.21
$0.411.48%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 92.06% | 74.81% | -15.86% | -40.70% | -188.64% |
| Total Depreciation and Amortization | 39.46% | 33.56% | 21.75% | 11.22% | 13.04% |
| Total Amortization of Deferred Charges | -4.93% | 0.41% | 0.41% | 0.41% | 0.41% |
| Total Other Non-Cash Items | -85.32% | -67.19% | 124.45% | 152.66% | 155.51% |
| Change in Net Operating Assets | 77.79% | 6.41% | 53.37% | -1,040.93% | -147.38% |
| Cash from Operations | 115.91% | 78.47% | 60.04% | 49.46% | 15.19% |
| Capital Expenditure | -- | -152.23% | -127.77% | -100.00% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -71.92% | -67.48% | -95.14% | -81.88% | 78.08% |
| Cash from Investing | -71.92% | -67.78% | -95.21% | -81.93% | 78.08% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -73.48% | 5,283.24% | 6,090.11% | 3,447.46% | -28.38% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00% | 10.98% | 19.82% | 27.03% | -109.93% |
| Cash from Financing | -124.00% | 18,394.85% | 57,158.50% | 11,570.59% | -36.26% |
| Foreign Exchange rate Adjustments | 350.93% | 35.73% | 206.01% | -108.57% | -146.09% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 9,510.03% | 169.11% | 211.09% | 115.78% | 110.22% |